View Filing Data

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Jun. 30, 2014	Aug. 11, 2014
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q2
Trading Symbol	ASMB
Entity Common Stock, Shares Outstanding		8,688,059
Entity Registrant Name	ASSEMBLY BIOSCIENCES, INC.
Entity Central Index Key	0001426800
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 21,316,328	$ 27,061,268
Advances to Assembly Pharmaceuticals, Inc	259,921	0
Other current assets	171,554	63,672
Total current assets	21,747,803	27,124,940
Computer equipment, net	7,399	7,102
Total assets	21,755,202	27,132,042
Current liabilities:
Accounts payable	1,421,353	2,614,619
Accrued expenses	48,435	23,435
Total current liabilities	1,469,788	2,638,054
Commitments
Stockholders' equity:
Preferred stock, $.001 par value; 5,000,000 shares authorized; 0 and 44,000 issued and outstanding at June 30, 2014 and December 31, 2013, respectively	0	44
Common stock, $.001 par value; 50,000,000 shares authorized; 4,679,251 and 4,146,779 issued and outstanding at June 30, 2014 and December 31, 2013, respectively	4,679	4,147
Additional paid-in capital	138,174,448	135,844,320
Common stock issuable, 25,000 shares at June 30, 2014 and December 31, 2013	368,750	368,750
Accumulated deficit	(118,262,463)	(111,723,273)
Total stockholders' equity	20,285,414	24,493,988
Total liabilities and stockholders' equity	$ 21,755,202	$ 27,132,042

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2014	Dec. 31, 2013
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, issued	0	44,000
Preferred stock, shares outstanding	0	44,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	4,679,251	4,146,779
Common stock, shares outstanding	4,679,251	4,146,779
Common stock issuable shares	25,000	25,000

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Operating expenses:
Research and development	$ 1,095,644	$ 3,508,450	$ 4,069,334	$ 6,117,553
General and administrative	1,410,500	1,300,309	2,546,961	2,460,174
Loss from operations	(2,506,144)	(4,808,759)	(6,616,295)	(8,577,727)
Interest income	36,871	56,871	77,105	102,744
Interest expense:
Net loss	$ (2,469,273)	$ (4,751,888)	$ (6,539,190)	$ (8,474,983)
Basic and diluted net loss per common share	$ (0.52)	$ (1.20)	$ (1.43)	$ (2.30)
Weighted average common shares outstanding - basic and diluted	4,704,251	3,944,496	4,562,384	3,679,276

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities:
Net loss	$ (6,539,190)	$ (8,474,983)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	566,335	979,575
Stock-based payments to consultants	1,177	22,190
Depreciation	2,292	2,678
Changes in operating assets and liabilities:
Other current assets	(367,803)	(117,939)
Accounts payable and accrued expenses	(1,168,266)	(160,075)
Net cash used in operating activities	(7,505,455)	(7,748,554)
Cash flows from investing activities:
Purchase of office and computer equipment	(2,589)	(5,166)
Net cash used in investing activities	(2,589)	(5,166)
Cash flows from financing activities:
Net proceeds from sale of common and preferred stock	1,763,104	20,754,418
Net cash provided by financing activities	1,763,104	20,754,418
Net (decrease) increase in cash and cash equivalents	(5,744,940)	13,000,698
Beginning of period	27,061,268	20,489,219
End of period	$ 21,316,328	$ 33,489,917

Organization, Business and Basis of Presentation

6 Months Ended

Jun. 30, 2014

Organization, Business and Basis Of Presentation [Abstract]

Organization, Business and Basis of Presentation

Note 1 - Organization, Business and Basis of Presentation:

Organization and business:

Assembly Biosciences, Inc. (“Assembly” or the “Company”) (formerly known as Ventrus Biosciences, Inc.) is a biopharmaceutical company developing novel therapies for infectious diseases and other disorders of the gastrointestinal system. To date, the Company has not generated any revenue nor had income producing activities. Assembly was incorporated in the State of Delaware on October 7, 2005 and commenced operations in April 2007. On July 11, 2014, the Company’s wholly owned subsidiary merged with and into Assembly Pharmaceuticals, Inc. (the “Assembly Merger”), with Assembly Pharmaceuticals, Inc. as the surviving entity. In connection with the Assembly Merger, on July 11, 2014, the Company changed its name from Ventrus Biosciences, Inc. to Assembly Biosciences, Inc.

Assembly is focused on treating certain infectious diseases that are particularly difficult to treat and control, determined to forge a new and different path and overcome the limitations of conventional approaches to treating these conditions. Assembly’s initial target is the hepatitis B virus, or HBV, with a specific goal of helping patients find a clinical cure. Assembly Pharmaceuticals, Inc. (with which we merged on July 11, 2014) has discovered a series of new compounds, known as core protein allosteric modulators, or CpAMs, that are capable of targeting and altering certain key proteins of HBV. These core proteins are involved in several steps of the HBV lifecycle and are essential for HBV’s continued regeneration and survival. Modulation of these core proteins with Assembly’s CpAMs has demonstrated preclinical proof of principle: multiple cell models have shown that CpAMs can selectively reduce the production of viral antigens—viral proteins responsible for common symptoms related to HBV—as well as reduce viral load—infectious viral particles circulating in the bloodstream.

Assembly’s second lead program is based on a new platform for targeted oral delivery of microbiome therapy agents to combat a type of infectious diarrhea called clostridium difficile-associated diarrhea, or CDAD. This delivery platform aims to deliver several types of beneficial bacteria, viruses, proteins and other small molecules to the gastrointestinal, or GI, tract—specifically the colon and/or the terminal ileum. The technology exploits recent data on nuanced differences in pH throughout the GI tract from the stomach to the distal colon, as well as recent advances in encapsulation technologies.

Reverse Stock Split

The Company effected a 1-for-5 reverse stock split of the Company’s common stock on July 11, 2014. All references to common stock, shares outstanding, average number of shares outstanding and per share amounts in these condensed consolidated financial statements and notes to condensed consolidated financial statements have been restated to reflect the 1-for-5 reverse stock split on a retroactive basis.

Basis of presentation:

The accompanying consolidated financial statements include the accounts and results of operations of Assembly Biosciences, Inc. and its wholly owned subsidiary, Assembly Acquisition, Inc., which was incorporated on May 5, 2014 in anticipation of the planned Assembly Merger. The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). All intercompany balances and transactions have been eliminated in consolidation.

The accompanying condensed balance sheet as of December 31, 2013, which has been derived from the Company’s audited financial statements, and the unaudited interim condensed consolidated financial statements, have been prepared in accordance with U.S. generally accepted accounting principles and the rules and regulations of the Securities and Exchange Commission (“SEC”) related to a quarterly report on Form 10-Q. Certain information and note disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to make the information presented not misleading. The unaudited interim consolidated financial statements reflect all adjustments which, in the opinion of management, are necessary for a fair presentation of the results for the periods presented. All such adjustments are of a normal and recurring nature. These unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 filed on March 31, 2014. The operating results presented in these unaudited condensed consolidated financial statements are not necessarily indicative of the results that may be expected for any future periods.

Capital Resources:

The Company has not derived any revenue from product sales to date as our products have not been approved for sale by the FDA or any foreign regulatory agency. Since inception, the Company’s operations have been financed primarily through the sale of equity securities, the proceeds from the exercise of warrants and stock options and issuance of debt. The Company has incurred losses from operations and negative cash flows since inception and expects to continue to incur substantial losses for the next several years as it continues its product development efforts. Management believes the Company currently has sufficient funds to meet its operating requirements for the next twelve months. If the Company cannot generate significant cash from its operations, it intends to obtain any additional funding it requires through strategic relationships, public or private equity or debt financings, or other arrangements and it cannot assure such funding will be available on reasonable terms, or at all.

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2014

Summary Of Significant Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2 - Summary of Significant Accounting Policies:

Cash and Cash Equivalents:

All highly liquid investments with maturities of three months or less at the time of purchase are considered to be cash equivalents. All of the Company’s cash equivalents have liquid markets and high credit ratings. The Company maintains its cash in bank deposit and other accounts, the balances of which, at times and at June 30, 2014, exceed federally insured limits.

Use of estimates:

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Significant estimates inherent in the preparation of the accompanying financial statements include the fair value of stock options and warrants granted to employees, consultants, directors, investors, licensors, placement agents and underwriters.

Additionally, the Company provides a valuation allowance for deferred income tax assets when it is considered more likely than not that all or a portion of such deferred income tax assets will not be realized.

Stock-based compensation:

The Company’s share-based compensation cost is measured at grant date, using the Black-Scholes option pricing model to estimate the fair values of the stock option awards, and the Monte Carlo valuation model to estimate the fair value of the restricted stock grant. Stock based compensation is recognized as expense over the employee’s or director’s requisite service period on a straight-line basis. The Company accounts for stock options and warrants granted to non-employees on a fair value basis which is estimated using the Black-Scholes option pricing model. The initial non-cash charge to operations for non-employee options and warrants with vesting are revalued at the end of each reporting period until vested and recognized as consulting expense over the related vesting period.

Research and development:

Research and development expenses include personnel and facility-related expenses, third party contracted services including clinical trial costs, manufacturing and process development costs, research costs and other consulting services. Research and development costs are expensed as incurred. In instances where the Company enters into agreements with third parties for clinical trials, manufacturing and process development, research and other consulting activities, costs are expensed as services are performed. Amounts due under such arrangements may be either fixed fee or fee for service, and may include upfront payments, monthly payments, and payments upon the completion of milestones or receipt of deliverables.

The Company’s accruals for clinical trials are based on estimates of the services received and pursuant to contracts with the respective clinical trial centers and clinical research organizations. In the normal course of business, the Company contracts with third parties to perform various clinical trial activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events, the successful enrollment of patients, and the completion of portions of the clinical trial or similar conditions. The objective of the Company’s accrual policy is to match the recording of expenses in its financial statements to the actual services received. As such, expense accruals related to clinical trials are recognized based on an estimate of the degree of completion of the event or events specified in the specific clinical study or trial contract.

Income taxes:

The Company’s income tax expense consists of current and deferred income tax expense or benefit. Current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when it is more likely than not that some or all of the deferred tax assets will not be realized.

Loss per common share:

Basic net loss per common share excludes dilution and is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity unless inclusion of such shares would be anti-dilutive. Since the Company has only incurred losses, basic and diluted net loss per share is the same. The number of potentially dilutive securities (options, warrants, restricted stock units and preferred stock) excluded from the diluted loss per share calculation for the three month periods ended June 30, 2014 and 2013 was 3,814,170 and 4,983,126 and six-month periods ended June 30, 2014 and 2013 was 3,814,170 and 5,518,126, respectively.

Recently Adopted Accounting standards:

In June 2014, the FASB issued Accounting Standard Update No. 2012-10, Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. The amendments in this update remove the definition of a development stage entity from the Master Glossary of the Accounting Standards Codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development state activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. A public entity is required to apply the amendments for annual reporting periods beginning after December 15, 2014, and interim periods therein. An entity should apply the amendments retrospectively for all comparative periods presented. Early adoption is permitted. The guidance became effective for the Company in the second quarter of 2014. Adoption of this standard did not have a material impact on the Company’s financial position, statement of operations, or statement of cash flows.

Stockholders' Equity

6 Months Ended

Jun. 30, 2014

Stockholders' Transactions [Abstract]

Stockholders' Equity

Note 4 - Stockholders’ Equity:

Common Stock Transactions:

The Company filed a shelf registration statement with the Securities and Exchange Commission, which became effective on February 10, 2012, under which it may offer shares of its common stock and preferred stock, various series of debt securities and/or warrants to purchase any of such securities, either individually or in units, in one or more offerings, up to a total dollar amount of $100,000,000. As part of the shelf registration statement, the Company included a prospectus for an at-the-market common equity sales program for the sale of up to $20,000,000 of common stock. From May 2012 through December 2013, the Company sold an aggregate of 1,630,849 shares of common stock and 44,000 shares of Series A Non-Voting Preferred Stock, convertible into 440,000 shares of common stock, under the shelf, resulting in net proceeds of approximately $28,566,000. In January 2014, the Company sold an aggregate of 92,473 shares of common stock under the amended at-the-market common equity sales program, resulting in net proceeds of approximately $1,763,000. As of June 30, 2014, an aggregate of approximately $70,000,000 worth of securities was available under the shelf registration statement out of which approximately $15,000,000 of common stock was available for the at-the-market common equity sales program. However, pursuant to SEC rules, because the Company’s publicly held shares had a market value of less than $75,000,000 as of June 30, 2014, the Company is limited to selling under the shelf in any 12-month period an amount of securities equal to one-third of the market value of its publicly held shares, which, as of June 30, 2014, was approximately $10,100,000.

Preferred Stock Transactions:

The Series A non-voting convertible preferred shares had a liquidation preference of $0.001 per share and each share of Series A preferred stock was convertible into 10 common shares of the Company’s common stock at any time at the holder’s option. During February 2014, all 44,000 outstanding shares of Series A preferred stock converted into an aggregate of 440,000 shares of the Company’s common stock.

Common Stock Options and Warrants:

Warrants

In connection with the Company’s financings from 2007 to 2010, the Company issued warrants to investors and/or placement agents to purchase shares of common stock as well as certain consultants.

A summary of the Company’s warrant activity and related information is as follows:

	Six Months Ended June 30, 2014
			Weighted Average
	Shares		Exercise Price
Outstanding at beginning of period		172,209	$	38.85
Expired		(20,973)	$	33.00
Outstanding at end of period		151,236	$	39.65
Warrants exercisable at end of period		151,236	$	39.65

Common Stock

On April 5, 2013, the Company granted restricted stock units to four employees under the 2010 Plan for an aggregate of 100,000 shares of common stock. Of these units, 25% vested immediately at the grant date. The remaining 75% of the units will vest in equal 25% tranches if the 20 trading day volume-weighted average price of our common stock as reported on the NASDAQ Capital Market is at least $20.75, $25.75 and $30.75, respectively. The performance period for the unvested restricted stock units ends on June 30, 2016; if one or more of the stock price thresholds are not met by that date the unvested units will expire. Each employee elected to defer receipt of all shares issuable under the units, including the immediately vested shares, (these shares are shown as issuable at June 30, 2014) until the earliest of termination of employment, a change in control of Assembly, or April 1, 2015. The restricted stock units were issued to employees and officers at a price equal to the market price of the Company’s stock at the date of grant. The Company estimated the fair value of the restricted stock units using the Monte Carlo valuation model with the following assumptions; volatility of 56.10% , risk free interest rate of 1.934%, and dividend rate of 0%. The total estimated fair value of the restricted stock units was approximately $1,135,000. Compensation costs for restricted stock award are being recognized on a straight-line basis over the performance period. The first 25% of restricted stock grant was immediately expensed.

A summary of the status of our restricted stock units as of June 30, 2014 is as follows:

	Six Months Ended June 30, 2014
			Weighted Average
	Shares		Grant Date Fair Value Per Share
Restricted stock units as of January 1, 2014		75,000	$	10.20
Restricted stock units as of June 30, 2014		75,000	$	10.20

Stock Options

In January 2014, the Company granted options to purchase an aggregate of 121,700 shares under the 2010 Plan to the Chief Executive Officer and the Chief Financial Officer at an exercise price of $19.05 per share. The Company also granted options to purchase 1,000 shares to a consultant at a price of $18.80.

A summary of the Company’s option activity and related information is as follows:

	Six Months Ended June 30, 2014
	Shares		Weighted Average Exercise Price		Aggregate Intrinsic Value
Outstanding at beginning of period		467,698	$	29.35	$	-
Granted		122,700	$	19.05	$	-
Exercised		-	$	-	$	-
Forfeited		(53,800)		36.10		-
Outstanding at end of period		536,598	$	26.30	$	-
Options exercisable at end of period

The fair value of the options granted for the six-month period ended June 30, 2014, was based on the following assumptions:

	2014
Risk-free interest rate		2.30	%
Expected volatility		51.29	%
Expected life of options		5 years
Expected dividend yield		0	%

Estimated future stock-based compensation expense relating to unvested stock options is as follows:

Calendar Years Ending December 31,	Future Stock Option Compensation Expense
2014 (July through December)	$	467,914
2015		613,353
2016		542,500
2017		63,500

Total estimated future stock-based compensation expense – stock options	$	1,687,267

The weighted average remaining contractual life of options outstanding at June 30, 2014 is approximately 7 years.

Stock-based compensation expensed to research and development expense for the three and six months ended June 30, 2014 and 2013 was $(4,335) and $ 73,976 (including reversal of charges related to unvested options which were forfeited) and $143,919 and $348,104, respectively. Stock-based compensation expensed to general and administrative expense for the three and six months ended June 30, 2014 and 2013 was $259,052 and $493,536 and $140,671 and $653,661 respectively.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2014

Summary Of Significant Accounting Policies [Abstract]

Cash and Cash Equivalents

Cash and Cash Equivalents:

Use of estimates

Use of estimates:

Stock-based compensation

Stock-based compensation:

Research and development

Research and development:

Income taxes

Income taxes:

Loss per common share

Loss per common share:

Recently Adopted Accounting standards:

Recently Adopted Accounting standards:

- Definition

Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.

+ References + Details

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References + Details

Stockholders' Equity (Tables)

6 Months Ended

Jun. 30, 2014

Schedule of Restricted Stock Units

A summary of the status of our restricted stock units as of June 30, 2014 is as follows:

	Six Months Ended June 30, 2014
			Weighted Average
	Shares		Grant Date Fair Value Per Share
Restricted stock units as of January 1, 2014		75,000	$	10.20
Restricted stock units as of June 30, 2014		75,000	$	10.20

Assumptions for Weighted Average Fair Value of Options Granted

The fair value of the options granted for the six-month period ended June 30, 2014, was based on the following assumptions:

	2014
Risk-free interest rate		2.30	%
Expected volatility		51.29	%
Expected life of options		5 years
Expected dividend yield		0	%

Estimated Future Stock Based Expenses Relating to Unvested Stock Options

Estimated future stock-based compensation expense relating to unvested stock options is as follows:

Calendar Years Ending December 31,	Future Stock Option Compensation Expense
2014 (July through December)	$	467,914
2015		613,353
2016		542,500
2017		63,500

Total estimated future stock-based compensation expense – stock options	$	1,687,267

Stock Option [Member]

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award

A summary of the Company’s option activity and related information is as follows:

	Six Months Ended June 30, 2014
	Shares		Weighted Average Exercise Price		Aggregate Intrinsic Value
Outstanding at beginning of period		467,698	$	29.35	$	-
Granted		122,700	$	19.05	$	-
Exercised		-	$	-	$	-
Forfeited		(53,800)		36.10		-
Outstanding at end of period		536,598	$	26.30	$	-
Options exercisable at end of period

Warrant [Member]

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award

A summary of the Company’s warrant activity and related information is as follows:

	Six Months Ended June 30, 2014
			Weighted Average
	Shares		Exercise Price
Outstanding at beginning of period		172,209	$	38.85
Expired		(20,973)	$	33.00
Outstanding at end of period		151,236	$	39.65
Warrants exercisable at end of period		151,236	$	39.65

Stockholders' Equity - Additional Information (Details) - USD ($)			1 Months Ended	3 Months Ended		6 Months Ended		20 Months Ended
	Jul. 10, 2014	Apr. 05, 2013	Jan. 31, 2014	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Feb. 10, 2012
Stockholders Equity Note [Line Items]
Shelf Registration Offering Amount									$ 100,000,000
Option granted exercise price						$ 19.05
Stock option, weighted average remaining contractual life						7 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						122,700
Preferred Stock, Conversion Basis						A preferred stock was convertible into 10 common shares of the Companys common stock at any time at the holders option.
Fair Value Assumptions, Risk Free Interest Rate						2.30%
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total						$ 1,135,000
Restricted Stock Expensed Percentage						25.00%
Proceeds From The Sale Of Common Stock At Net Of Offering Costs			$ 1,763,000
Shelf Registration Common Stock Offered Amount				$ 10,100,000		$ 10,100,000
Shelf Registration Securities Available For Issuance Number				70,000,000		70,000,000
Common Stocks, Including Additional Paid in Capital				$ 75,000,000		$ 75,000,000
Subsequent Event [Member]
Stockholders Equity Note [Line Items]
Option granted exercise price	$ 7.20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	2,560,000
Preferred Stock [Member]
Stockholders Equity Note [Line Items]
Preferred stock 44,000 shares converted to 440,000 Common stock shares (in shares)						44,000
Additional Paid-in Capital [Member]
Stockholders Equity Note [Line Items]
Net proceeds raised from common stock issued in a public offering								$ 28,566,000
Series A Preferred Stock [Member]
Stockholders Equity Note [Line Items]
Preferred Stock, Liquidation Preference Per Share				$ 0.001		$ 0.001
Preferred stock 44,000 shares converted to 440,000 Common stock shares (in shares)								44,000
Common Stock [Member]
Stockholders Equity Note [Line Items]
Preferred stock 44,000 shares converted to 440,000 Common stock shares (in shares)								1,630,849
Shelf Registration Securities Available For Issuance Number				15,000,000		15,000,000
Preferred stock 44,000 shares converted to 440,000 Common stock shares (in shares)						440,000
Consultants [Member]
Stockholders Equity Note [Line Items]
Option granted exercise price			$ 18.80
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			1,000
Research and Development Expense [Member]
Stockholders Equity Note [Line Items]
Stock based compensation expense				$ (4,335)	$ 73,976	$ 143,919	$ 348,104
General and Administrative Expenses [Member]
Stockholders Equity Note [Line Items]
Stock based compensation expense				$ 259,052	$ 493,536	$ 140,671	$ 653,661
At-The-Market Common Equity Sales Program [Member]
Stockholders Equity Note [Line Items]
Shelf Registration Common Stock Offered Amount									$ 20,000,000
Amended At-The-Market Common Equity Sales Program [Member] \| Common Stock [Member]
Stockholders Equity Note [Line Items]
Preferred stock 44,000 shares converted to 440,000 Common stock shares (in shares)			92,473
Equity Incentive Plan 2010 [Member]
Stockholders Equity Note [Line Items]
Stock options granted			121,700
Equity Incentive Plan 2010 [Member] \| Chief Executive Officer [Member]
Stockholders Equity Note [Line Items]
Option granted exercise price			$ 19.05
Restricted Stock Units (RSUs) [Member]
Stockholders Equity Note [Line Items]
Percentage Of Restricted Stock Units Vested Descriptions		25% vested immediately at the grant date. The remaining 75% of the units will vest in equal 25% tranches if the 20 trading day volume-weighted average price of our common stock as reported on the NASDAQ Capital Market is at least $20.75, $25.75 and $30.75, respectively.
Fair Value Assumptions, Expected Volatility Rate						56.10%
Fair Value Assumptions, Risk Free Interest Rate						1.934%
Fair Value Assumptions, Expected Dividend Rate						0.00%
Restricted Stock Units (RSUs) [Member] \| Four Employees [Member]
Stockholders Equity Note [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		100,000

Option Activity and Related Information (Details)	6 Months Ended
Option Activity and Related Information (Details)	Jun. 30, 2014 USD ($) $ / shares shares
Shares
Option, Outstanding at beginning of period \| shares	467,698
Option, Granted \| shares	122,700
Options, Exercised \| shares	0
Options, Forfeited \| shares	(53,800)
Option, Outstanding at end of period \| shares	536,598
Weighted Average Exercise Price
Option, Outstanding at beginning of period	$ 29.35
Option, Granted	19.05
Option, Exercised	0
Option, Forfeited	36.10
Option, Outstanding at end of period	$ 26.30
Aggregate Intrinsic Value
Option, Outstanding at beginning of period \| $	$ 0
Option, Granted	$ 0
Option, Exercised \| $	$ 0
Option, Outstanding at end of period \| $	$ 0

Subsequent Event - Additional Information (Details) - USD ($)			6 Months Ended
	Jul. 11, 2014	Jul. 10, 2014	Jun. 30, 2014
Subsequent Event [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross			122,700
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price			$ 19.05
Subsequent Event [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities	4,008,848
Common Stock Exercisable	621,651
Common Stock, Capital Shares Reserved for Future Issuance		2,560,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period		514,445
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit		$ 12.35
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit		78.85
Weighted Average Price Of Common Stock1		$ 20.75
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross		2,560,000
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price		$ 7.20
Weighted Average Price Of Common Stock2		25.75
Weighted Average Price Of Common Stock3		$ 30.75
Subsequent Event [Member] \| Restricted Stock Units (RSUs) [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period		75,000
Subsequent Event [Member] \| President [Member]
Subsequent Event [Line Items]
Labor and Related Expense	$ 350,000
Maximum Percentage Of Bonus From Base Salary	50.00%
Retention Bonus Payable	$ 150,000
Subsequent Event [Member] \| Chief Medical Officer [Member]
Subsequent Event [Line Items]
Labor and Related Expense	290,000
Retention Bonus Payable	100,000
Subsequent Event [Member] \| Chief Scientific Officer [Member]
Subsequent Event [Line Items]
Labor and Related Expense	$ 315,000
Maximum Percentage Of Bonus From Base Salary	30.00%

Commitments - Additional Information (Details)	6 Months Ended
Commitments - Additional Information (Details)	Jun. 30, 2014 USD ($)
Chief Executive Officer [Member]
Commitments and Contingencies Disclosure [Line Items]
Annual base Salary	$ 475,000
Annual performance-based bonus, percentage	50.00%
Chief Financial Officer [Member]
Commitments and Contingencies Disclosure [Line Items]
Annual base Salary	$ 300,000
Annual performance-based bonus, percentage	50.00%

License Agreements - Additional Information (Details)	6 Months Ended
License Agreements - Additional Information (Details)	Jun. 30, 2014 USD ($)
Subsequent Event [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payment For Nonrefundable License Fee	$ 300,000
S.L.A. Pharma [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Potential milestone payment	$ 20,000,000

Warrant Activity and Related Information (Details)	6 Months Ended
Warrant Activity and Related Information (Details)	Jun. 30, 2014 $ / shares shares
Shares
Warrant, Outstanding at beginning of period \| shares	172,209
Warrant, Expired \| shares	(20,973)
Warrant, Outstanding at end of period \| shares	151,236
Warrants exercisable at end of period \| shares	151,236
Weighted Average Exercise Price
Warrant, Outstanding at beginning of period \| $ / shares	$ 38.85
Warrant, Expired \| $ / shares	33.00
Warrant, Outstanding at end of period \| $ / shares	39.65
Warrants exercisable at end of period \| $ / shares	$ 39.65

Common Stock Restricted Stock Units (Details) - Restricted Stock [Member] - $ / shares	Jun. 30, 2014	Dec. 31, 2013
Stockholders Equity Note [Line Items]
Common Stock Shares, Restricted stock units	75,000	75,000
Weighted Average Grant Date Fair Value Per Share, Restricted stock units	$ 10.20	$ 10.20

Assumptions for Fair Value of Options Granted (Details)	6 Months Ended
Assumptions for Fair Value of Options Granted (Details)	Jun. 30, 2014
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]
Risk-free interest rate	2.30%
Expected volatility	51.29%
Expected life of options	5 years
Expected dividend yield	0.00%

Estimated Future Stock-Based Compensation Expense Relating to Unvested Stock Options (Details)	Jun. 30, 2014 USD ($)
Preferred stock 44,000 shares converted to 440,000 Common stock shares (in shares)
2014 (July through December)	$ 467,914
2015	613,353
2016	542,500
2017	63,500
Total estimated future stock-based compensation expense - stock options	$ 1,687,267